Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.

Kovtun Y, Jones GE, Adams S, Harvey L, Audette CA, Wilhelm A, Bai C, Rui L, Laleau R, Liu F, Ab O, Setiady Y, Yoder NC, Goldmacher VS, Chari RVJ, Pinkas J, Chittenden T.

Blood Adv. 2018 Apr 24;2(8):848-858. doi: 10.1182/bloodadvances.2018017517.

2.

IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Ab O, Whiteman KR, Bartle LM, Sun X, Singh R, Tavares D, LaBelle A, Payne G, Lutz RJ, Pinkas J, Goldmacher VS, Chittenden T, Lambert JM.

Mol Cancer Ther. 2015 Jul;14(7):1605-13. doi: 10.1158/1535-7163.MCT-14-1095. Epub 2015 Apr 22.

3.

High-affinity accumulation of a maytansinoid in cells via weak tubulin interaction.

Goldmacher VS, Audette CA, Guan Y, Sidhom EH, Shah JV, Whiteman KR, Kovtun YV.

PLoS One. 2015 Feb 11;10(2):e0117523. doi: 10.1371/journal.pone.0117523. eCollection 2015.

4.

Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates.

Goldmacher VS, Amphlett G, Wang L, Lazar AC.

Mol Pharm. 2015 Jun 1;12(6):1738-44. doi: 10.1021/mp5007536. Epub 2015 Feb 17.

PMID:
25635630
5.

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.

Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C, Dumontet C, Plesa A, Chiron M, Lejeune P, Chittenden T, Park PU, Blanc V.

Clin Cancer Res. 2014 Sep 1;20(17):4574-83. doi: 10.1158/1078-0432.CCR-14-0695. Epub 2014 Jul 1.

6.

The isolation and characterization of renal cancer initiating cells from human Wilms' tumour xenografts unveils new therapeutic targets.

Pode-Shakked N, Shukrun R, Mark-Danieli M, Tsvetkov P, Bahar S, Pri-Chen S, Goldstein RS, Rom-Gross E, Mor Y, Fridman E, Meir K, Simon A, Magister M, Kaminski N, Goldmacher VS, Harari-Steinberg O, Dekel B.

EMBO Mol Med. 2013 Jan;5(1):18-37. doi: 10.1002/emmm.201201516. Epub 2012 Dec 13.

7.

Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer.

Zhao RY, Erickson HK, Leece BA, Reid EE, Goldmacher VS, Lambert JM, Chari RV.

J Med Chem. 2012 Jan 26;55(2):766-82. doi: 10.1021/jm201284m. Epub 2012 Jan 5.

PMID:
22148292
8.

Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates.

Zhao RY, Wilhelm SD, Audette C, Jones G, Leece BA, Lazar AC, Goldmacher VS, Singh R, Kovtun Y, Widdison WC, Lambert JM, Chari RV.

J Med Chem. 2011 May 26;54(10):3606-23. doi: 10.1021/jm2002958. Epub 2011 May 4.

PMID:
21517041
9.
10.

Antibody-maytansinoid conjugates designed to bypass multidrug resistance.

Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK, Erickson HK, Sun X, Wilhelm S, Ab O, Lai KC, Widdison WC, Kellogg B, Johnson H, Pinkas J, Lutz RJ, Singh R, Goldmacher VS, Chari RV.

Cancer Res. 2010 Mar 15;70(6):2528-37. doi: 10.1158/0008-5472.CAN-09-3546. Epub 2010 Mar 2.

11.

The effect of the cell death suppressor vMIA on the production of a recombinant protein in the adenovirus-293 expression system.

Vieira HL, Cunha L, Goldmacher VS, Alves PM.

Protein Expr Purif. 2009 Apr;64(2):179-84. doi: 10.1016/j.pep.2008.11.004. Epub 2008 Nov 18.

PMID:
19041945
12.

The murine cytomegalovirus cell death suppressor m38.5 binds Bax and blocks Bax-mediated mitochondrial outer membrane permeabilization.

Arnoult D, Skaletskaya A, Estaquier J, Dufour C, Goldmacher VS.

Apoptosis. 2008 Sep;13(9):1100-10. doi: 10.1007/s10495-008-0245-2.

PMID:
18670882
13.

Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy.

Ishitsuka K, Jimi S, Goldmacher VS, Ab O, Tamura K.

Br J Haematol. 2008 Apr;141(1):129-31. doi: 10.1111/j.1365-2141.2008.07000.x. Epub 2008 Feb 12. No abstract available.

PMID:
18279455
14.

Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.

Reddy JA, Westrick E, Santhapuram HK, Howard SJ, Miller ML, Vetzel M, Vlahov I, Chari RV, Goldmacher VS, Leamon CP.

Cancer Res. 2007 Jul 1;67(13):6376-82.

15.

Cell killing by antibody-drug conjugates.

Kovtun YV, Goldmacher VS.

Cancer Lett. 2007 Oct 8;255(2):232-40. Epub 2007 Jun 5. Review.

PMID:
17553616
16.

Structure-function analysis of the interaction between Bax and the cytomegalovirus-encoded protein vMIA.

Pauleau AL, Larochette N, Giordanetto F, Scholz SR, Poncet D, Zamzami N, Goldmacher VS, Kroemer G.

Oncogene. 2007 Nov 1;26(50):7067-80. Epub 2007 May 14.

PMID:
17496930
17.

Cytopathic effects of the cytomegalovirus-encoded apoptosis inhibitory protein vMIA.

Poncet D, Pauleau AL, Szabadkai G, Vozza A, Scholz SR, Le Bras M, Brière JJ, Jalil A, Le Moigne R, Brenner C, Hahn G, Wittig I, Schägger H, Lemaire C, Bianchi K, Souquère S, Pierron G, Rustin P, Goldmacher VS, Rizzuto R, Palmieri F, Kroemer G.

J Cell Biol. 2006 Sep 25;174(7):985-96. Epub 2006 Sep 18.

18.

Semisynthetic maytansine analogues for the targeted treatment of cancer.

Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, Zhao R, Wang L, Blättler WA, Chari RV.

J Med Chem. 2006 Jul 13;49(14):4392-408.

PMID:
16821799
19.

Processing of human cytomegalovirus UL37 mutant glycoproteins in the endoplasmic reticulum lumen prior to mitochondrial importation.

Mavinakere MS, Williamson CD, Goldmacher VS, Colberg-Poley AM.

J Virol. 2006 Jul;80(14):6771-83.

20.

Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K, Lutz RJ, Goldmacher VS, Blättler WA.

Cancer Res. 2006 Apr 15;66(8):4426-33.

21.

Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, Goldmacher VS.

Cancer Res. 2006 Mar 15;66(6):3214-21.

22.

Cell death suppression by cytomegaloviruses.

Goldmacher VS.

Apoptosis. 2005 Mar;10(2):251-65. Review.

PMID:
15843887
23.

A clinically relevant SCID-hu in vivo model of human multiple myeloma.

Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC.

Blood. 2005 Jul 15;106(2):713-6. Epub 2005 Apr 7.

24.

Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors.

Baloglu E, Miller ML, Roller EE, Cavanagh EE, Leece BA, Goldmacher VS, Chari RV.

Bioorg Med Chem Lett. 2004 Dec 6;14(23):5885-8.

PMID:
15501062
25.

Synthesis of taxoids with improved cytotoxicity and solubility for use in tumor-specific delivery.

Miller ML, Roller EE, Zhao RY, Leece BA, Ab O, Baloglu E, Goldmacher VS, Chari RV.

J Med Chem. 2004 Sep 23;47(20):4802-5.

PMID:
15369381
26.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC.

Blood. 2004 Dec 1;104(12):3688-96. Epub 2004 Aug 3.

PMID:
15292058
27.

Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies.

Miller ML, Roller EE, Wu X, Leece BA, Goldmacher VS, Chari RV, Ojima I.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):4079-82.

PMID:
15225730
28.

Cell death suppressors encoded by cytomegalovirus.

Goldmacher VS.

Prog Mol Subcell Biol. 2004;36:1-18. Review. No abstract available.

PMID:
15171604
29.

Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria.

Arnoult D, Bartle LM, Skaletskaya A, Poncet D, Zamzami N, Park PU, Sharpe J, Youle RJ, Goldmacher VS.

Proc Natl Acad Sci U S A. 2004 May 25;101(21):7988-93. Epub 2004 May 17.

30.

An anti-apoptotic viral protein that recruits Bax to mitochondria.

Poncet D, Larochette N, Pauleau AL, Boya P, Jalil AA, Cartron PF, Vallette F, Schnebelen C, Bartle LM, Skaletskaya A, Boutolleau D, Martinou JC, Goldmacher VS, Kroemer G, Zamzami N.

J Biol Chem. 2004 May 21;279(21):22605-14. Epub 2004 Mar 5.

32.

Tumor-specific novel taxoid-monoclonal antibody conjugates.

Ojima I, Geng X, Wu X, Qu C, Borella CP, Xie H, Wilhelm SD, Leece BA, Bartle LM, Goldmacher VS, Chari RV.

J Med Chem. 2002 Dec 19;45(26):5620-3.

PMID:
12477344
33.

vMIA, a viral inhibitor of apoptosis targeting mitochondria.

Goldmacher VS.

Biochimie. 2002 Feb-Mar;84(2-3):177-85. Review.

PMID:
12022948
34.

A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation.

Skaletskaya A, Bartle LM, Chittenden T, McCormick AL, Mocarski ES, Goldmacher VS.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7829-34. Epub 2001 Jun 26.

35.

The sequence and antiapoptotic functional domains of the human cytomegalovirus UL37 exon 1 immediate early protein are conserved in multiple primary strains.

Hayajneh WA, Colberg-Poley AM, Skaletskaya A, Bartle LM, Lesperance MM, Contopoulos-Ioannidis DG, Kedersha NL, Goldmacher VS.

Virology. 2001 Jan 5;279(1):233-40.

36.

A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2.

Goldmacher VS, Bartle LM, Skaletskaya A, Dionne CA, Kedersha NL, Vater CA, Han JW, Lutz RJ, Watanabe S, Cahir McFarland ED, Kieff ED, Mocarski ES, Chittenden T.

Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12536-41.

37.

Folate-maytansinoids: target-selective drugs of low molecular weight.

Ladino CA, Chari RV, Bourret LA, Kedersha NL, Goldmacher VS.

Int J Cancer. 1997 Dec 10;73(6):859-64.

38.

Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.

Goulet AC, Goldmacher VS, Lambert JM, Baron C, Roy DC, Kouassi E.

Blood. 1997 Sep 15;90(6):2364-75.

PMID:
9310487
40.
41.

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.

Liu C, Tadayoni BM, Bourret LA, Mattocks KM, Derr SM, Widdison WC, Kedersha NL, Ariniello PD, Goldmacher VS, Lambert JM, Blättler WA, Chari RV.

Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8618-23.

42.

Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors.

O'Connor R, Liu C, Ferris CA, Guild BC, Teicher BA, Corvi C, Liu Y, Arceci RJ, Goldmacher VS, Lambert JM, Blättler WA.

Blood. 1995 Dec 1;86(11):4286-94.

PMID:
7492789
43.

Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation.

Chari RV, Jackel KA, Bourret LA, Derr SM, Tadayoni BM, Mattocks KM, Shah SA, Liu C, Blättler WA, Goldmacher VS.

Cancer Res. 1995 Sep 15;55(18):4079-84.

44.

Ricin A chain can be chemically cross-linked to the mammalian ribosomal proteins L9 and L10e.

Vater CA, Bartle LM, Leszyk JD, Lambert JM, Goldmacher VS.

J Biol Chem. 1995 May 26;270(21):12933-40.

45.

Expression and secretion of a recombinant ricin immunotoxin from murine myeloma cells.

Krek CE, Ladino CA, Goldmacher VS, Blättler WA, Guild BC.

Protein Eng. 1995 May;8(5):481-9.

PMID:
8532670
46.

Characterization of antibody binding to cell surface antigens using a plasma membrane-bound plate assay.

Vater CA, Reid K, Bartle LM, Goldmacher VS.

Anal Biochem. 1995 Jan 1;224(1):39-50.

PMID:
7535987
47.

Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.

Goldmacher VS, Bourret LA, Levine BA, Rasmussen RA, Pourshadi M, Lambert JM, Anderson KC.

Blood. 1994 Nov 1;84(9):3017-25.

PMID:
7524764
48.

Mutational and structural analysis of the lectin activity in binding domain 2 of ricin B chain.

Lehar SM, Pedersen JT, Kamath RS, Swimmer C, Goldmacher VS, Lambert JM, Blättler WA, Guild BC.

Protein Eng. 1994 Oct;7(10):1261-6.

PMID:
7855142
49.

A cytotoxicity assay utilizing a fluorescent dye that determines accurate surviving fractions of cells.

Sellers JR, Cook S, Goldmacher VS.

J Immunol Methods. 1994 Jun 24;172(2):255-64.

PMID:
8034974
50.

Humanization of murine monoclonal antibodies through variable domain resurfacing.

Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blättler WA, Rees AR, Guild BC.

Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):969-73.

Supplemental Content

Loading ...
Support Center